Cover Image
Market Research Report

Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast to 2028

Published by DelveInsight Business Research LLP Product code 905936
Published Content info 87 Pages
Delivery time: 1-2 business days
Price
Back to Top
Focal Segmental Glomerulosclerosis (FSGS) - Epidemiology Forecast to 2028
Published: August 1, 2019 Content info: 87 Pages
Description

DelveInsight's 'Focal Segmental Glomerulosclerosis (FSGS)-Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Focal Segmental Glomerulosclerosis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Focal Segmental Glomerulosclerosis Epidemiology

The Focal Segmental Glomerulosclerosis epidemiology division provide insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Focal Segmental Glomerulosclerosis are studied through all possible division to give a better understanding of the disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Focal Segmental Glomerulosclerosis Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by Total Prevalent cases, Gender-specific cases, Type-specific cases [Primary, Secondary], and Age-specific cases [Children, Adult] in the 7MM.

According to DelveInsight, the total prevalent cases of Focal Segmental Glomerulosclerosis were 196,333 in 2017 in 7MM.

Report Scope

  • The report covers a detailed overview of Focal Segmental Glomerulosclerosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The report provides insight into the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, and the UK), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Focal Segmental Glomerulosclerosis.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by type-specific cases and age-specific cases of Focal Segmental Glomerulosclerosis in 7MM.

Key strengths

  • 10 Year Forecast of Focal Segmental Glomerulosclerosis epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Focal Segmental Glomerulosclerosis
  • Prevalent Cases according to segmentation: type-specific cases and age-specific cases

Key assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Table of Contents
Product Code: DIEI0368

Table of Contents

1. Key Insights

2. Focal Segmental Glomerulosclerosis (FSGS): Epidemiology Overview at a Glance

  • 2.1. Patient Share (%) Distribution of FSGS in 2017
  • 2.2. Patient Share (%) Distribution of FSGS in 2028

3. Disease Overview: Focal Segmental Glomerulosclerosis

  • 3.1. Introduction
  • 3.2. Classification of FSGS
  • 3.3. Signs and Symptoms
  • 3.4. Histopathology
  • 3.5. Etiology
  • 3.6. Pathogenesis
  • 3.7. Biomarkers
  • 3.8. Diagnosis of FSGS
    • 3.8.1. Differential Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Prevalent Patient Population of Focal Segmental Glomerulosclerosis
  • 4.3. Country Wise-Epidemiology of Focal Segmental Glomerulosclerosis
  • 4.4. United States
    • 4.4.1. Assumptions and Rationale
    • 4.4.2. Prevalent Cases of Focal Segmental Glomerulosclerosis in the United States
    • 4.4.3. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in the US
    • 4.4.4. Type-Specific Cases of Focal Segmental Glomerulosclerosis in the US
    • 4.4.5. Age-Specific Cases of Focal Segmental Glomerulosclerosis in the US
  • 4.5. EU5
    • 4.5.1. Assumptions and Rationale
  • 4.6. Germany
    • 4.6.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in Germany
    • 4.6.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in Germany
    • 4.6.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in Germany
    • 4.6.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in Germany
  • 4.7. France
    • 4.7.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in France
    • 4.7.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in France
    • 4.7.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in France
    • 4.7.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in France
  • 4.8. Italy
    • 4.8.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in Italy
    • 4.8.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in Italy
    • 4.8.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in Italy
    • 4.8.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in Italy
  • 4.9. Spain
    • 4.9.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in Spain
    • 4.9.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in Spain
    • 4.9.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in Spain
    • 4.9.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in Spain
  • 4.10. United Kingdom
    • 4.10.1. Prevalent Cases of Focal Segmental Glomerulosclerosis in the United Kingdom
    • 4.10.2. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in the United Kingdom
    • 4.10.3. Type-Specific Cases of Focal Segmental Glomerulosclerosis in the UK
    • 4.10.4. Age-Specific Cases of Focal Segmental Glomerulosclerosis in the UK
  • 4.11. Japan
    • 4.11.1. Assumptions and Rationale
    • 4.11.2. Prevalent Cases of Focal Segmental Glomerulosclerosis in Japan
    • 4.11.3. Gender-Specific Cases of Focal Segmental Glomerulosclerosis in Japan
    • 4.11.4. Type-Specific Cases of Focal Segmental Glomerulosclerosis in Japan
    • 4.11.5. Age-Specific Cases of Focal Segmental Glomerulosclerosis in Japan

5. Unmet Needs

6. Market Drivers

7. Market Barriers

8. Appendix

9. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

13. Disclaimer

List of Tables

  • Table 1: Characteristic clinical and pathology features of the six forms of FSGS
  • Table 2: Causes of focal segmental glomerulosclerosis
  • Table 3: Genes related to FSGS or nephrotic syndrome
  • Table 4: Diagnostic protein biomarker candidates for FSGS
  • Table 5: Prognostic candidate biomarkers
  • Table 6: Differential diagnoses of FSGS
  • Table 7: Prevalent Patient Population of Focal Segmental Glomerulosclerosis in 7MM (2017-2028)
  • Table 8: Prevalent Cases of FSGS in the United States (2017-2028)
  • Table 9: Gender-specific cases of FSGS in the United States (2017-2028)
  • Table 10: Type-specific Cases of FSGS in the United States (2017-2028)
  • Table 11: Age-specific Cases of FSGS in the United States (2017-2028)
  • Table 12: Diagnosed Prevalent Cases of FSGS in Germany (2017-2028)
  • Table 13: Gender-specific cases of FSGS in Germany (2017-2028)
  • Table 14: Type-specific Cases of FSGS in Germany (2017-2028)
  • Table 15: Age-specific Cases of FSGS in Germany (2017-2028)
  • Table 16: Prevalent Cases of FSGS in France (2017-2028)
  • Table 17: Gender-specific cases of FSGS in France (2017-2028)
  • Table 18: Type-specific Cases of FSGS in France (2017-2028)
  • Table 19: Age-specific Cases of FSGS in France (2017-2028)
  • Table 20: Prevalent Cases of FSGS in Italy (2017-2028)
  • Table 21: Gender-specific cases of FSGS in Italy (2017-2028)
  • Table 22: Type-specific Cases of FSGS in Italy (2017-2028)
  • Table 23: Age-specific Cases of FSGS in Italy (2017-2028)
  • Table 24: Diagnosed Prevalent Cases of FSGS in Spain (2017-2028)
  • Table 25: Gender-specific cases of FSGS in Spain (2017-2028)
  • Table 26: Type-specific Cases of FSGS in Spain (2017-2028)
  • Table 27: Age-specific Cases of FSGS in Spain (2017-2028)
  • Table 28: Prevalent Cases of FSGS in the United Kingdom (2017-2028)
  • Table 29: Gender-specific cases of FSGS in the United Kingdom (2017-2028)
  • Table 30: Type-specific Cases of FSGS in the UK (2017-2028)
  • Table 31: Age-specific Cases of FSGS in the UK (2017-2028)
  • Table 32: Prevalent Cases of FSGS in Japan (2017-2028)
  • Table 33: Gender-specific cases of FSGS in Japan (2017-2028)
  • Table 34: Type-specific Cases of FSGS in Japan (2017-2028)
  • Table 35: Age-specific Cases of FSGS in Japan (2017-2028)

List of Figures

  • Figure 1: Focal Segmental Glomerulosclerosis
  • Figure 2: Common symptoms of Lupus
  • Figure 3: Histopathology of minimal change disease and focal segmental glomerulosclerosis
  • Figure 4: Pathogenesis of FSGS
  • Figure 5: Prevalent Patient Population of Focal Segmental Glomerulosclerosis in 7MM (2017-2028)
  • Figure 6: Prevalent Cases of FSGS in the United States (2017-2028)
  • Figure 7: Gender-specific Prevalent Cases of FSGS in the US (2017-2028)
  • Figure 8: Type-specific Diagnosed Prevalent Cases of FSGS in the US (2017-2028)
  • Figure 9: Age-specific Cases of FSGS in the US (2017-2028)
  • Figure 10: Prevalent Cases of FSGS in Germany (2017-2028)
  • Figure 11: Gender-specific of FSGS in Germany (2017-2028)
  • Figure 12: Type-specific Diagnosed Prevalent Cases of FSGS in Germany (2017-2028)
  • Figure 13: Age-specific Cases of FSGS in Germany (2017-2028)
  • Figure 14: Prevalent Cases of FSGS in France (2017-2028)
  • Figure 15: Gender-specific Cases of FSGS in France (2017-2028)
  • Figure 16: Type-specific Prevalent Cases of FSGS in France (2017-2028)
  • Figure 17: Age-specific Cases of FSGS in France (2017-2028)
  • Figure 18: Prevalent Cases of FSGS in Italy (2017-2028)
  • Figure 19: Gender-specific Cases of FSGS in Italy (2017-2028)
  • Figure 20: Type-specific Diagnosed Prevalent Cases of FSGS in Italy (2017-2028)
  • Figure 21: Age-specific Cases of FSGS in Italy (2017-2028)
  • Figure 22: Prevalent Cases of FSGS in Spain (2017-2028)
  • Figure 23: Gender-specific Cases of FSGS in Spain (2017-2028)
  • Figure 24: Type-specific Diagnosed Prevalent Cases of FSGS in Spain (2017-2028)
  • Figure 25: Age-specific Cases of FSGS in Spain (2017-2028)
  • Figure 26: Prevalent Cases of FSGS in the United Kingdom (2017-2028)
  • Figure 27: Gender-specific Cases of FSGS in the United Kingdom (2017-2028)
  • Figure 28: Type-specific Diagnosed Prevalent Cases of FSGS in the UK (2017-2028)
  • Figure 29: Age-specific Cases of FSGS in the UK (2017-2028)
  • Figure 30: Prevalent Cases of FSGS in Japan (2017-2028)
  • Figure 31: Gender-specific Cases of FSGS in Japan (2017-2028)
  • Figure 32: Type-specific Diagnosed Prevalent Cases of FSGS in Japan (2017-2028)
  • Figure 33: Age-specific Cases of FSGS in Japan (2017-2028)
Back to Top